PAB fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Patrys Ltd. engages in the commercialization of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. Its pipeline includes PAT-DX1 antibody fragment, PAT-DX3 full sized antibody, and PAT-DX1-NP conjugated to nanoparticles. The company was founded by Daniel Devine on December 8, 2006 and is headquartered in South Melbourne, Australia.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
PAB has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company